Program Introduction: Fighting Cancer with Off-the-Shelf iPSC Immunotherapies

Dan Shoemaker

Dr. Shoemaker opened the session by discussing the tremendous promise of cell-based therapeutics in the fight against cancer, particularly as demonstrated by clinical successes in the CAR-T space over the past few years. He also described the many hurdles inherent in developing patient-specific therapies beyond early clinical proof of concept studies, and how an iPSC-driven strategy represents an ideal solution to overcoming these challenges and limitations, and may facilitate the development of effective and consistent “off-the-shelf” products.